alphagan p
(brimonidine tartrate)Allergan, Inc.
Usage: ALPHAGAN P (brimonidine tartrate ophthalmic solution) is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
36 results
alrex
(loteprednol etabonate)Bausch & Lomb IncorporatedUsage: ALREX ophthalmic suspension is indicated for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis.amjevita
(adalimumab-atto)Amgen IncUsage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.beovu
(brolucizumab)Novartis Pharmaceuticals CorporationUsage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).bromsite
(bromfenac)Sun Pharmaceutical Industries, Inc.Usage: BromSite (bromfenac ophthalmic solution) 0.075% is indicated for treating postoperative inflammation and preventing ocular pain in patients who have undergone cataract surgery.cequa
(cyclosporine)Sun Pharmaceutical Industries, Inc.Usage: CEQUA ophthalmic solution is indicated for increasing tear production in patients with keratoconjunctivitis sicca (dry eye) as a calcineurin inhibitor immunosuppressant.cimerli
(ranibizumab-eqrn)Coherus BioSciences IncUsage: CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.combigan
(brimonidine tartrate, timolol maleate)Allergan, Inc.Usage: COMBIGAN (brimonidine tartrate/timolol maleate) is indicated for reducing elevated intraocular pressure in patients with glaucoma or ocular hypertension. It serves as adjunctive or replacement therapy for those with inadequately controlled IOP, dosed twice daily for optimal effectiveness.cosopt pf
(dorzolamide hydrochloride and timolol maleate)Thea Pharma Inc.Usage: COSOPT® PF is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who do not adequately respond to beta-blockers. It is typically administered twice daily and offers a different IOP-lowering effect compared to standard therapies.cyltezo
(adalimumab-adbm)Boehringer Ingelheim Pharmaceuticals, Inc.Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.